HERV-K Antigens, Antibodies, and Methods
Methods and compositions for cancer diagnostics and therapy are provided. More particular, methods and compositions for detecting, preventing, and treating HERV-K + cancers are provided. One example of a method may involve a method for preventing or inhibiting cancer cell proliferation by administering to a subject a cancer cell proliferation blocking or reducing amount of a HERV-K env protein binding antibody.
1 . An antibody that binds to HERV-K env protein.
2 . An antibody according to claim 1 , which is chimeric.
3 . An antibody according to claim 1 , which is humanly acceptable.
4 . An antibody according to claim 1 , which is conjugated to an anti-tumor agent.
5 . An antibody according to claim 1 , which is a monoclonal antibody.
6 . A single chain antibody that binds to HERV-K env protein.
7 . An antibody according to claim 6 , which is chimeric.
8 . An antibody according to claim 6 , which is humanly acceptable.
9 . An antibody according to claim 6 , which is conjugated to an anti-tumor agent.
10 . An antibody which binds to an epitope of HERV-K env protein.
11 . An oligonucleotide which binds under high stringency conditions to a polynucleotide encoding HERV-K env protein.
12 . An oligonucleotide according to claim 11 , wherein said oligonucleotide is non-naturally occurring.
13 . A vector comprising an oligonucleotide according to claim 11 .
14 . A pharmaceutical composition comprising a therapeutically effective amount of at least one of an antibody according to claim 1 .
15 . A pharmaceutical composition comprising a therapeutically effective amount of at least one of an oligonucleotide according to claim 11 .
16 . A pharmaceutical composition comprising a therapeutically effective amount of at least one of a vector according to claim 13 .
17 . A method for preventing or inhibiting cancer cell proliferation, said method comprising administering to a subject a cancer cell proliferation blocking or reducing amount of a HERV-K env protein binding antibody.
18 . A method according to claim 17 , wherein the HERV-K env protein binding antibody blocks proliferation of breast cancer cells, ovarian cancer cells, or malignant melanoma cells.
19 . A method for diagnosing or staging or monitoring cancer, the method comprising determining the level of HERV-K env protein on a cancer cell present in a tissue suspected of being positive for cancer and comparing the level to the level of HERV-K env protein on normal tissue, whereby an increase in the level of HERV-K env protein in the suspect tissue over the level of HERV-K env protein in the normal tissue indicates the presence of cancer in the suspect tissue.
20 . A method according to claim 19 , wherein said level of the HERV-K env protein is determined by exposing the suspect and the normal tissues to a HERV-K env protein binding antibody and comparing the amount of antibody bound by each tissue, wherein an increase in the level of bound antibody by the suspect tissue over the level of bound antibody by the normal tissue indicates the presence of cancer in the suspect tissue.
21 . A method for screening a compound that inhibits or prevents HERV-K + cancer cell proliferation, the method comprising determining a first amount of HERV-K env protein expressed by HERV-K + cancer cells exposed to the compound, wherein the HERV-K + cancer cells overexpress HERV-K env protein; and comparing the first amount of HERV-K env protein to a second amount of HERV-K env protein expressed by the HERV-K + cancer cells that have not been exposed to the compound; whereby the first amount being less than the second amount indicates that the compound may inhibit or prevent HERV-K + cancer cell proliferation.
22 . A method for preventing or inhibiting cancer cell proliferation, said method comprising administering to a subject a cancer cell proliferation blocking or reducing amount of a HERV-K env protein binding antibody.
23 . A method for providing a target for T cells or B cells comprising providing a HERV-K env protein.
24 . The method of claim 23 wherein the HERV-K env protein elicits a CD4 + T cell response or a CD8 + T cell response.
25 . The method of claim 23 wherein the HERV-K env protein, or portion thereof, serves as an epitope for HLA class I capable of eliciting CD4 + and CD8 + T cell responses.
26 . The method of claim 23 wherein the HERV-K env protein, or portion thereof, serves as an epitope capable of eliciting Th1 cytokine secretion.
27 . The method of claim 23 wherein the HERV-K env protein, or portion thereof, serves as an epitope capable of eliciting Th2 cytokine secretion, chemokine secretion, or both.
28 . The method of claim 23 wherein the HERV-K env protein elicits granzyme B secretion.
29 . The method of claim 23 wherein the HERV-K env protein is used to activate vaccines.
30 . The method of claim 23 wherein the HERV-K env protein used for adoptive T cell therapies.
31 . A method for stimulating PBMCs comprising providing autologous DCs pulsed with HERV-K env antigen, maturing the PBMCs to produce antigen specific IVS, and promoting the ability of the HERV-K specific PBMCs to stimulate anti-cancer T-cell proliferation.
32 . A kit for diagnosing or staging cancer, the kit comprising an antibody according to claim 1 .
33 . A kit for diagnosing or staging cancer, the kit comprising an oligonucleotide according to to claim 11 .
34 . A kit for screening compounds that inhibits or prevents HERV-K + cancer cell proliferation, the kit comprising an antibody according to claim 1.